A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs SAR 405838 (Primary)
- Indications Liposarcoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
- 10 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 10 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 17 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Feb 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History